Key result
Acetylsalicylic acid for CAD faces clinical challenges from variable response and high platelet reactivity.
Why the study?
Attention is increasingly focused on the variability of response and resistance to antiplatelet therapy such as acetylsalicylic acid in coronary artery disease, which increases ischemic risk.
This review highlights the role of acetylsalicylic acid in CAD treatment and addresses the clinical challenge of antiplatelet resistance and high platelet reactivity.
Variable acetylsalicylic acid response in CAD warrants clinical vigilance; leaves open optimal strategies for high platelet reactivity.
Coronary artery disease (CAD) is leading due to disability and death of the working population, and successful its treatment is largely determined by maintaining adequate coronary blood flow, including through interventions, percutaneous interventions. Acetylsalicylic acid is widely used in patients with coronary artery disease (CAD) to prevent major adverse cardiac events (MACE). Lately, attention is increasingly being paid to the variability of the response to antiplatelet therapy. High platelet reactivity increases the risk of ischemic events. The causes of resistance to antiplatelet agents are heterogeneous and multicomponent: clinical, cellular and genetic. This review article describes features and characteristics of the using acetylsalicylic acid- aspirin in CAD, as well as current problems in the antiplatelet therapy.
No takes yet. Share an insight, caveat, or question.
Anis et al. (2020) conducted a review in Coronary artery disease (CAD). Acetylsalicylic acid (aspirin) was evaluated. This review highlights the role of acetylsalicylic acid in coronary artery disease treatment, emphasizing the clinical challenge of variable response and high platelet reactivity to antiplatelet therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: